Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

17.27 -0.23 (-1.31%)

Delayed Quote Updated: 11:22 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

36 37 Next >

10 Health Care Stocks Whale Activity In Today's Session ↗

June 19, 2024

Via Benzinga

A Glimpse Into The Expert Outlook On Sarepta Therapeutics Through 9 Analysts ↗

June 14, 2024

Via Benzinga

Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test ↗

June 13, 2024

Sarepta is now just awaiting the FDA's decision on whether to fully approve its gene therapy, and for whom.

Via Investor's Business Daily

Exit Strategy: 3 Overvalued Stocks to Sell Before They Deflate ↗

June 06, 2024

These are the overvalued stocks to sell. They represent quality companies that are worth buying after a 20% to 30% downside

Via InvestorPlace

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 31, 2024

From Sarepta Therapeutics, Inc.

Via Business Wire

12 Analysts Have This To Say About Sarepta Therapeutics ↗

May 20, 2024

Via Benzinga

What Analysts Are Saying About Sarepta Therapeutics Stock ↗

May 02, 2024

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

May 31, 2024

Via Benzinga

Why Sarepta Therapeutics Stock Is Rising Today ↗

May 30, 2024

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stock is trading higher on Thursday after it was announced the company will be added to the S&P MidCap 400.

Via Benzinga

Topics Stocks

Sarepta Downgraded As FDA Decision Date Approaches, Shares Up 50% Over Last Six Months ↗

May 28, 2024

RBC Capital Markets downgrades Sarepta Therapeutics following increased FDA label expansion expectations for Elevidys and recent stock surge.

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 24, 2024

Via Benzinga

The 2030 Millionaire’s Club: 3 Biotech Stocks to Buy Now ↗

May 23, 2024

With interest cuts on the horizon, it's a prime time to consider these high-risk-high-reward biotech stocks to buy.

Via InvestorPlace

Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

May 28, 2024

Via Benzinga

Jim Cramer: This Industrial Stock Is Doing 'Very Well'; Here's His Take On Palantir ↗

May 22, 2024

Jim Cramer likes Enbridge Inc. (NYSE: ENB), says Lazard, Inc. (NYSE: LAZ) is a good buy, and Advanced Drainage Systems, Inc. (NYSE: WMS) is an incredible infrastructure play. He also mentions Jacobs...

Via Benzinga

Why Dyne Therapeutics, With A 108% Run This Year, Just Catapulted Again ↗

May 20, 2024

Dyne Therapeutics is looking to take on Sarepta Therapeutics in DMD.

Via Investor's Business Daily

3 Biotech Stocks With the Potential to Make You an Overnight Millionaire ↗

May 04, 2024

Don’t miss out on these stocks that could rock your portfolio with massive growth following FDA approvals and breakthrough treatments.

Via InvestorPlace

Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health

May 03, 2024

From Sarepta Therapeutics, Inc.

Via Business Wire

Apple, Kellanova And 3 Stocks To Watch Heading Into Thursday ↗

May 02, 2024

Via Benzinga

SRPT Stock Earnings: Sarepta Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗

May 01, 2024

SRPT stock results show that Sarepta Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Sarepta Therapeutics (SRPT) Q1 2024 Earnings Call Transcript ↗

May 01, 2024

SRPT earnings call for the period ending March 31, 2024.

Via The Motley Fool

Topics Earnings

Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments

May 01, 2024

From Sarepta Therapeutics, Inc.

Via Business Wire

1 Top Growth Stock to Buy and Hold for 10 Years ↗

May 01, 2024

This company's lineup might look very different in a decade, but the end result will be the same for investors.

Via The Motley Fool

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 30, 2024

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Stock Shows Improved Technical Strength ↗

April 29, 2024

The Relative Strength (RS) Rating for Sarepta Therapeutics stock headed into a new percentile Monday, as it got a lift from 70 to 73.

Via Investor's Business Daily

Sarepta Therapeutics to Announce First Quarter 2024 Financial Results

April 24, 2024

From Sarepta Therapeutics, Inc.

Via Business Wire

Why Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst ↗

April 08, 2024

Sarepta stock has taken a beating this year, and it might not be over with the first-quarter report looming.

Via Investor's Business Daily

2 Biotech Stocks to Buy Hand Over Fist in April ↗

April 06, 2024

These drugmakers have made important moves over the past year.

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

April 04, 2024

Via Benzinga

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 29, 2024

From Sarepta Therapeutics, Inc.

Via Business Wire

How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback ↗

March 28, 2024

The company could follow Sarepta Therapeutics with a gene therapy for Duchenne muscular dystrophy.

Via Investor's Business Daily

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

36 37 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.